In conclusion, our study demonstrated that SPARC played crucial roles in tumor progression and metastasis of ESCC and downregulation of SPARC expression could decrease cell migration and invasion via suppression of EMT through the inhibition of p-FAK/p-ERK pathway that might be a novel therapeutic target against ESCC. The gene discussed is PTK2; the disease is neoplasm.